Abeona Therapeutics Inc. (ABEO) SEC filings

ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3039% below fair value

$2.42+0.13 (+5.68%)

Close on Nov 13, 2026Market cap $138.39MP/E –Yield –

SEC filings

40 of Abeona Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Sep 15, 2026	Sep 15, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 11, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 10, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 4, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 27, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 7, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 20, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 18, 2025	Jul 18, 2025	SEC EDGAR
Current report	8-K	Jun 27, 2025	Jul 2, 2025	SEC EDGAR
Current report	8-K	May 19, 2025	May 19, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	May 15, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	May 9, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	Apr 29, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Apr 29, 2025	Apr 29, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2024	Apr 9, 2025	SEC EDGAR
Current report	8-K	Mar 20, 2025	Mar 20, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 20, 2025	SEC EDGAR
Current report	8-K	Dec 20, 2024	Dec 20, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Nov 14, 2024	Nov 14, 2024	SEC EDGAR
Proxy statement	DEF 14A	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 8, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Oct 28, 2024	Oct 29, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 14, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Abeona Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jul 5, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABEO.

Compare: ABEO vs KROS · ABEO vs LXRX · ABEO vs AQST · ABEO vs STOK · ABEO vs VRDN

Gross margin65.1% · median 82.1%

Operating margin-186.1% · median -181.3%

Net margin-160.3% · median -162.3%

Company	Revenue	Growth
AQST	$48.84M	+12.5%
KROS	$40.42M	-83.4%
ABEO	$39.01M	–
LXRX	$38.54M	-45.6%
STOK	$27.59M	-86.2%
VRDN	$26.31M	-62.8%

Company

Next earnings (est.): Mar 16, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 226
Held by institutions: 77.9%
Auditor: Deloitte & Touche LLP
SEC CIK: 318306

Advertisement
300 × 250

See a number that looks wrong?